Akebia Therapeutics (AKBA) Capital Leases (2013 - 2014)

Akebia Therapeutics (AKBA) posted quarterly Capital Leases of $6369.0 for Q2 2014, down 13.51% quarter-over-quarter from $7364.0 in Q1 2014.

Akebia Therapeutics (AKBA) Capital Leases (2013 - 2014) Analysis & Trends

Akebia Therapeutics (AKBA) has reported Capital Leases for 2 consecutive years, with $6369.0 the latest figure, recorded in Q2 2014.

In Q2 2014, Capital Leases changed N/A year-over-year to $6369.0; the TTM figure through Jun 2014 stood at $6369.0 (changed N/A YoY), while the FY2013 annual figure was $8004.0, changed N/A from the prior year.
Capital Leases fell to $6369.0 in Q2 2014 per AKBA's latest filing, from $7364.0 in the prior quarter.
Across five years, Capital Leases topped out at $8004.0 in Q4 2013 and bottomed at $6369.0 in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-
10	Akebia Therapeutics	247.60 Mn	92.06 Mn	38.70 Mn

Download Data